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o-GlcNAc transferase Inhibition 
Differentially Affects Breast Cancer 
Subtypes
Anna Barkovskaya1,2, Kotryna seip1, Bylgja Hilmarsdottir1,3, Gunhild M. Maelandsmo1,4, 
Siver A. Moestue2,5 & Harri M. Itkonen  6
Post-translational modification of intracellular proteins with a single N-acetylglucosamine sugar 
(O-GlcNAcylation) regulates signaling, proliferation, metabolism and protein stability. In breast 
cancer, expression of the enzyme that catalyzes O-GlcNAcylation – O-GlcNAc-transferase (OGT), and 
the extent of protein O-GlcNAcylation, are upregulated in tumor tissue, and correlate with cancer 
progression. Here we compare the significance of O-GlcNAcylation in a panel of breast cancer cells 
of different phenotypes. We find a greater dependency on OGT among triple-negative breast cancer 
(TNBC) cell lines, which respond to OGT inhibition by undergoing cell cycle arrest and apoptosis. 
Searching for the cause of this response, we evaluate the changes in the proteome that occur after OGT 
inhibition or knock-down, employing a reverse-phase protein array (RPPA). We identify transcriptional 
repressor - hairy and enhancer of split-1 (HES1) - as a mediator of the OGT inhibition response in the 
TNBC cells. Inhibition of OGT as well as the loss of HES1 results in potent cytotoxicity and apoptosis. 
The study raises a possibility of using OGT inhibition to potentiate DNA damage in the TNBC cells.
Breast cancer is the most prevalent cancer type and the second leading cancer-related cause of death in women1. 
Course of treatment and prognosis depend on the histopathological evaluation of the hormone receptor status 
- estrogen receptor-α (ER), progesterone receptor (PR) and over-expression of human epidermal growth factor 
receptor 2 (HER2)2,3. 10–20% of breast cancers lack expression of the hormone receptors and do not over-express 
HER2. This sub-group is referred to as triple-negative breast cancers (TNBC)4. These tumors frequently have a 
basal-like phenotype, mutations in BRCA1 and tend to be more aggressive and invasive5,6. Patients with TNBC 
tumors do not stand to benefit from hormone therapy or HER2 inhibitors7, leaving them with limited therapeutic 
options and poor overall survival6,8.
O-GlcNAcylation is a post-translational protein modification. A sole known enzyme, O-GlcNAc transferase 
(OGT), catalyzes the transfer of β-N-acetylglucosamine (O-GlcNAc) from UDP-GlcNAc onto serine and threo-
nine residues of intracellular proteins9. Protein O-GlcNAcylation is reversible; removal of O-GlcNAc is catalyzed 
by the enzyme termed N-Acetyl-Beta-D-Glucosaminidase (OGA)10–12. Previous studies have implicated protein 
O-GlcNAcylation in promotion of the cancer hallmarks by sustaining growth and invasion13, regulating DNA 
damage- and stress-responses14,15 and controlling cell cycle progression16–18. O-GlcNAcylation is increased in 
most malignant tumors, including breast cancer, where it positively correlates with tumor progression18,19. It has 
been shown that both ER20,21 and PR22 are O-GlcNAcylated. An increase of the total O-GlcNAc levels, achieved 
through inhibition of OGA, can protect breast cancer cells from ER inhibitors23. However, it is not known if cer-
tain breast cancer subtypes are more dependent on protein O-GlcNAcylation or whether inhibition of OGT could 
be a useful therapeutic opportunity for some of the patients.
Here, we set out to compare the impact of OGT inhibition on proliferation and survival of breast cancer cells 
of different subtypes. In a panel of two receptor-positive and five TNBC cell lines, inhibition of OGT, either with 
a small-molecule inhibitor or through an siRNA-mediated knock-down, led to a more prominent cell death 
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and growth inhibition in the TNBC cells. To understand the nature of the higher sensitivity of the TNBC cells 
to OGT inhibition, we performed reverse phase protein array (RPPA) profiling. We identified a transcriptional 
repressor − hairy and enhancer of split-1 (HES1) as a protein selectively down-regulated in TNBC, but not in the 
receptor-positive cells in response to OGT inhibition. Knock-down of HES1 phenocopied cytotoxicity observed 
after OGT inhibition in TNBC cells. HES1 appears to have a specific role in TNBC cells, having a strong associa-
tion with poor survival in this patient group.
Materials and Methods
Cell culture. Cell lines were purchased from ATCC (Rockville, MD), maintained in humidified incubators at 
37 C° with 5% CO2 atmosphere and routinely tested for mycoplasma infections (PCR mycoplasma detection kit, 
Minerva Biolabs, Germany). Cells were cultured in the following media: MDA-MB-231 in RPMI-1640 supple-
mented with 5% fetal bovine serum (FBS) and 2 mM L-Alanyl L-Glutamine (g-max) (all purchased from Sigma 
Aldrich, St.Louis, MO); BT549 in RPMI-1640 with 10% FBS, g-max and 1 µg/ml human insulin (Sigma Aldrich); 
MCF7 in DMEM (Sigma Aldrich) with 10% FBS; T74D, MDA-MB-468, HCC38 and HCC70 in RPMI with 10% 
FBS and g-max. Cell line ID testing was performed by Genetica Labcorp (Burlington, NC).
Viability and cell proliferation assays. To evaluate the viability after treatment with inhibitors, cells 
were plated into 96-well plates using 5 × 104 MDA-MB-231, MDA-MB-468 and BT549, 3 × 104 HCC38, HCC70, 
MCF7 and T47D cells per well in a volume of 100 µl. The following day, the 2x concentrated inhibitors were intro-
duced in 100 µl of fresh respective growth media. Following 72 hours of incubation, the viability was measured 
using the CellTiter 96® AQueous One Solution (Promega, Madison, WI) Cell Proliferation Assay (MTS) according 
to the supplier’s protocol. To assess cell proliferation, the plates were kept in the IncuCyte® instrument (Essen 
BioScience, Hertfordshire, UK) which took images of each well every 3 hours and generated estimates of cell 
density expressed as percent of the total well area occupied by the cells.
Transient knockdowns. Reverse siRNA knockdowns were performed using two OGT siRNAs: s16094 and 
s16095; and two HES1 siRNAs: s6920 and s6921 (Thermo Fisher Scientific, Rockford, IL). 10 nM siRNA was 
mixed with 2 µl of Lipofectamine 3000® reagent (Invitrogen, Carlsbad, CA) in 360 µl Opti-MEM® reduced serum 
medium (Thermo Fisher Scientific) per well. The mixture was incubated for 20–30 minutes in room temperature 
and placed into 6-well culture plates. The cells were added to the plates in 2 ml of respective cell culture media, 
using 1,5 × 105 MDA-MB-231 and MDA-MB-468; 1,8 × 105 BT-549; 1,2 × 105 MCF7 or T47D cells per well.
Western blotting, immunoprecipitation and RPPA. For western blotting, cells were collected 
on ice using a scraper, washed in PBS and lyzed in RIPA buffer (50 mM Tris-HCl, pH7.4; 1% NP-40; 0.5% 
sodium-deoxycholate; 0.1% SDS; 150 mM NaCl) supplemented with phosphatase and protease inhibitors (Roche 
Applied Science, Mannheim, Germany) and 50 µM OGA inhibitor (PUGNAc, Sigma Aldrich). Following 
ultra-sonification, protein concentration of the samples was measured using the BCA protein assay kit (Pierce™, 
Thermo Scientific). 15–20 µg of protein was loaded per each gel lane. Membranes were visualized using the super 
signal West Dura kit (Thermo Scientific) in the Syngene G:Box instrument (Syngene, Cambridge, UK) with 
GeneSnap software. Densitometry was performed using ImageJ.
Reverse phase protein array (RPPA) was performed at the core facility of functional proteomics in MD 
Anderson Cancer Center, University of Texas, Houston TX. Protein lysate samples were prepared for anal-
ysis in accordance with the core facility’s instructions (available at https://www.mdanderson.org/research/
research-resources/core-facilities/functional-proteomics-rppa-core.html). Protein concentration was adjusted 
to 1.5 µg/ml, and 35–50 µl of each sample was submitted for analysis.
Gene expression analysis. For gene expression analysis, cells were collected on ice after 24 hours of treat-
ment. RNA was isolated using illustra RNA spin mini kit (GE healthcare, Chicago, IL), following the suppli-
er’s instructions. RNA concentration was measured using NanoDrop™ (Thermo Fisher Scientific). cDNA was 
derived using the qScript™ cDNA Synthesis Kit (Quanta Biosciences, Gaithersburg, MD), cDNA stock concen-
tration was adjusted to 7.14 ng/µl. Each qPCR reaction contained 2.5 µl of stock cDNA, 2.5 ul of 1 µM forward and 
reverse primer mix and 5 µl of Fast SYBR™ Green master mix (Thermo Fischer Scientific). The qPCR reaction 
was performed using a Bio-Rad CFX Connect™ Real Time PCR machine (Bio-Rad, Hercules, CA).
Cell cycle, TUNEL assay and Annexin V assay. Cells were collected on ice, washed with cold PBS and 
immediately fixed in ice-cold 100% methanol. Samples were stored at −20 °C until further use. TUNEL assay was 
performed using Terminal Transferase and Biotin-16-dUTP (both from Roche Diagnostics GmbH, Mannheim, 
Germany), following the supplied protocol supplemented with 10 mM DTT. Following the apoptosis staining, 
cells were incubated for 30 minutes at 37 C° with the 1.5 µg/ml Hoechst 33258 in PBS solution. This allowed for 
simultaneous analysis of the cell cycle. Samples were analyzed on the LSR II flow cytometer (BD Bioscience, San 
Jose, CA).
Annexin V flow-cytometry based assay was also used to measure the proportion of cells undergoing apop-
tosis (Trevigen®, Gaithersburg, MD). In the assay, the double-negative cells represent normal live cells with an 
intact membrane. Propidium iodide (PI) - positive cells have an impaired membrane and represent the cells 
going through either necrosis or late-stage apoptosis. FITC-conjugated Annexin V detects phosphatidylserine - a 
marker of apoptosis exposed on the outer surface of the cells.
Primers, antibodies and chemical reagents. The following primer sequences were used: 
OGT forward: CAGCATCCCAGCTCACTT, reverse: CAGCTTCACAGCTATGTCTTC; HES1 
for ward:  ACGTGCGAGGGCGT TAATAC,  reverse :  GGGGTAGGTCATGGCAT TGA;  O GA 
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forward: CGAGTGAACATTCCCATCACT, reverse: CCCAAAGGAGCACAGATGTT; PTEN forward: 
CGAACTGGTGTAATGATATGT, reverse: CATGAACTTGTCTTCCCGT.
The following antibodies from Cell Signaling Technology (Danvers, MA) were used: anti-OGT (#5368), 
anti-HES1 (#11988), anti-phospho-Ser235/236-S6 (#4858), anti-γ-H2AX (#9718), anti-PARP (#9542), and 
anti-Histone 3 (#4499). Mouse-derived anti-O-Linked N-Acetylglucosamine (RL2) (ab2739) was acquired from 
Abcam (Cambridge, UK). Mouse anti-α-tubulin (#CP06) was from Merck Millipore (Burlington, MA).
The following chemical compounds were used: OSMI1 compound was kindly provided by Professor Suzanne 
Walker (Harvard Medical School). Additional OSMI1 compound was purchased from Sigma Aldrich (SML1621). 
Efficacy of the two OSMI1 stocks was determined to be similar (data not shown); O-GlcNAcase inhibitor 
PUGNAc (A7229), MG132 proteasome inhibitor (M7449), mTORC1 inhibitor Everolimus (Ev) (SML2282) 
and PR inhibitor mifepristone (MF) (M8046), were purchased from Sigma Aldrich. γ-secretase inhibitor (GSI) 
RO4929097 was purchased from Selleckchem (S1575).
Generation of survival plots. Survival plots were generated using the online KM-plotter resource24. ER 
and PR expression were specified to separate the patient groups of interest. Systemically untreated patients were 
excluded from analysis.
Results
Hormone receptor-negative breast cancer cells are sensitive to OGT inhibition. Importance of 
OGT in breast cancer has been previously reported, however the diversity and molecular heterogeneity of breast 
cancer has never been taken into account. Here we compare the impact of OGT inhibition on a panel of breast 
cancer cells with a different hormone receptor status: ER- and PR-positive MCF7 and T47D; and receptor-neg-
ative MDA-MB-231, BT-549, MDA-MB-468, HCC38 and HCC70. In line with the previous reports, the OGT 
inhibitor, OSMI125, caused a decrease in total protein O-GlcNAcylation (Fig. 1A). Treatment caused a consistent 
30–60% decrease in total O-GlcNAcylation in all of the tested cell lines, and the response did not depend on the 
hormone receptor status.
After confirming that OSMI1 is able to inhibit OGT activity, we moved on to assess the effect of OGT inhibi-
tion on cell viability. OSMI1 strongly decreased the viability in all TNBC cell lines, with an average EC20 value of 
~7 µM (Fig. 1B,C). The strongest effect was observed in the MDA-MB-231 cell line, where treatment with 40 µM 
OSMI1 led to a complete loss of viability. Notably, the effect on the receptor-positive cell lines MCF7 and T47D, 
was less prominent, with the average EC20 value more than two times higher than in the TNBC cells, ~18 µM. 
Both the OGT knock-down and the treatment with OSMI1 altered cell morphology (Fig. 1D,E), indicating possi-
ble cell death in MDA-MB-231 and BT-549 cells, but not in the receptor-positive MCF7 and T47D cells. In order 
to test if the cell death was triggered in response to OGT inhibition, we measured apoptosis in the MDA-MB-231 
cells using TUNEL assay following a transient OGT knock-down. Indeed, we found a time-dependent induction 
of apoptosis (Fig. 1F). TUNEL assay detects DNA strand breaks that occur during apoptosis, however the DNA 
strand breaks can in some cases be repaired26. Therefore, we detected total length and cleaved PARP in order to 
corroborate the induction of apoptosis27. Both of the OGT-targeting siRNAs induced PARP cleavage, thereby 
confirming apoptosis in response to the OGT knockdown (Supplementary Fig. S1A).
Cell toxicity caused by the OGT inhibition was more prominent in the TNBC cells, while the effect on the 
receptor-positive MCF7 and T47D cells was much less pronounced. These data suggest that the hormone receptor 
status appears to be a strong determinant of sensitivity to OGT inhibition.
Progesterone receptor inhibitor sensitizes hormone receptor-positive cells to OSMI1. Focusing 
on the difference in the hormone receptor status between the cell lines, we set out to test if the hormone receptor 
inhibitors may be used to sensitize receptor-positive cells to OGT inhibition. First, we evaluated the effect of an 
ER inhibitor, tamoxifen, alone or in combination with OSMI1 on the viability of MCF7 cells. Tamoxifen modestly 
sensitized cells to OSMI1 (Fig. 2A), however the overall loss of cell viability was mild.
Next, we examined the combined effect of PR inhibitor, MF28 with OSMI1. A combination of MF with OSMI1 
led to an 80% decrease of cell viability (Fig. 2B). We confirmed that MF similarly sensitized another hormone 
receptor-positive cell line, T47D to OSMI1 (Fig. 2C). As expected, we did not observe an enhanced effect in the 
TNBC cell lines (Supplementary Fig. S1B).
OGT inhibition resulted in activation of cell death in MDA-MB-231 cells (Fig. 1F, Supplementary Fig. S1A). 
This prompted us to test if MF is able to enhance cell death induction by OSMI1 in the receptor-positive cells. 
Using Annexin V flow-cytometry assay, we found that the combination of OSMI1 with MF induced prominent 
cell death (Fig. 2D), as well as severe morphological changes indicative of cell death in MCF7 cells (Supplementary 
Fig. S1C). We noted an accumulation of propidium iodide - positive cells, which represents either cells going 
through late-stage apoptosis or necrosis29. We evaluated whether the cell death occurs through apoptosis or 
necrosis by using PARP cleavage-signature as a marker for these27,30. OSMI1-MF combination induced prominent 
accumulation of PARP fragments of 90 and 25 kDa (Fig. 2E), which are indicative of apoptosis. However, we did 
not observe accumulation of PARP cleavage fragments typical for necrosis. Based on these data, inhibition of PR 
sensitizes receptor-positive BC cells to OSMI1.
Next, we sought to understand the mechanism of this combined effect. PR has been shown to protect breast 
cancer cells from the radiation-induced cell death31, while OGT is known to suppress expansion of the DNA 
damage signaling15. These studies led us to hypothesize that the combined inhibition of OGT and PR results in 
DNA damage. To test this, we evaluated the induction of the canonical DNA damage marker γ-H2AX32. Indeed, 
OSMI1 significantly potentiated the DNA-damage induced by MF alone (Fig. 2E,F).
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OGT inhibition causes cell cycle arrest in breast cancer cells. To better understand the consequences 
of OGT inhibition in breast cancer cells, we compared the immediate effects on the proteome of the TNBC 
cells (MDA-MB-231) and the receptor-positive cells (MCF7). Both cell lines were treated with 20 µM OSMI1 for 
24 hours, or OGT siRNAs for 72 hours. Following the treatment, proteins were extracted and analyzed with an 
RPPA assay. To understand the high sensitivity of MDA-MB-231 cells to OGT inhibition, we selected the most 
up- and down-regulated proteins in this cell line, evaluating the relative changes in protein expression after treat-
ment with OSMI1 (Fig. 3A) and the OGT knock-down (Supplementary Fig. S2A). The most down-regulated pro-
tein was the phosphorylated ribosomal protein S6 (p-PS6). The functional role of PS6 phosphorylation remains a 
matter of debate, but it has been implicated in the regulation of cell size and glucose homeostasis33. We confirmed 
Figure 1. OGT inhibition is potently cytotoxic in TNBC cell lines. (A) Relative decrease in total protein 
O-GlcNAcylation, after 4 and 24 hours of treatment with 40 µM OSMI1 in six BC cell lines. Percentage 
above indicates median decrease compared to the respective DMSO-treated controls, at least 2 independent 
experiments. (B) Relative viability in BC cell lines after 72 hours of treatment with OSMI1. MTS assay. At 
least 3 biological replicates for each cell line. Error bars - SEM. TNBC lines marked in black and grey; triple-
positive cell lines in red. (C) EC50 and EC20 concentrations of OSMI1, mean from at least three independent 
experiments for each cell line. (D) OGT transient knock-down in four BC cell lines, representative out of at least 
three experiments. (E) BC cells pictured after 72 hours of treatment with 20 µM OSMI1, or 5 days of transient 
OGT knockdown. (F) Apoptotic population in MDA-MB-231 following 3, 4 and 5 days of transient OGT 
knock-down, TUNEL assay. Error bars - standard deviation, n = at least 2. *p < 0.05; **p < 0.005; ***p < 0.001 
unpaired t-test, comparing knock-down samples to the respective scr RNA control samples.
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that as the total O-GlcNAcylation decreases after treatment with OSMI1, the p-PS6 is strongly down-regulated in 
MDA-MB-231, but not in MCF7 (Fig. 3B). This effect is present as early as 16 hours following the treatment and 
results in a complete loss of p-PS6 after 48 hours (Fig. 3C).
PS6 is phosphorylated in response to activation of the mammalian target of rapamycin complex 1 
(mTORC1)34. To test whether PS6 phosphorylation mediates the cytotoxic response to OSMI1 treatment in the 
TNBC cells, we attempted to inhibit mTORC1 to sensitize the MCF7 cells to OGT inhibition. We treated both cell 
lines with OSMI1 alone and in combination with an mTORC1 inhibitor, Everolimus (Ev). mTORC1 inhibition 
strongly decreased the viability of the MCF7 cells, however, no combined effect of the dual treatment with OSMI1 
was present (Fig. 3D).
Figure 2. Progesterone receptor inhibitor sensitizes receptor-positive BC cells to OGT inhibition. (A) Relative 
viability in MCF7 after 72 hours of treatment with Tamoxifen (Tam), OSMI1, or a combination. MTS assay. 
Error bars - SEM, n = 3. *p < 0.05; **p < 0.005, unpaired t-test, comparing viability after the combination 
treatment to the viability after treatment with respective dose of tamoxifen. (B,C) Viability in MCF7 and T47D 
cells following 72 hours of treatment with Mifepristone (MF), OSMI1 or a combination, MTS assay. Error bars 
- SEM, n = 3. *p < 0.05; **p < 0.005; ***p < 0.001 unpaired t-test, comparing viability after the combination-
treatment to the viability after treatment with respective dose of MF. (D) Annexin V apoptosis assay in MCF7 
following 72 hours of treatment with MF, OSMI1 or a combination. FITC-/PI- population represents live cells; 
FITC+ cells are in early apoptosis; FITC+/PI+ cells are in late apoptosis; PI+ cells are necrotic. Error bars - 
standard deviation, n = 2. (E) Total length and cleaved PARP and γ-H2AX in MCF7 after 72 hours of treatment 
with MF, OSMI1, or a combination. Representative of two separate experiments. (F) Relative γ-H2AX protein 
expression in MCF7 following 72 hours of treatment with MF, OSMI1 or a combination. n = 3, error bars - 
SEM; unpaired t-test, comparing expression after the combination treatments to the expression after respective 
concentration of MF and OSMI1; *p < 0.05.
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In order to identify the pathways that control the increased sensitivity of MDA-MB-231 cells to OGT inhi-
bition, we submitted the list of proteins most differentially regulated by treatment with OSMI1, for the STRING 
pathway enrichment analysis35. Regulation of the mitotic cell cycle was identified as the most affected pathway 
(Supplementary Fig. S2B,D). We evaluated changes in the cell cycle distribution following OGT inhibition with 
OSMI1 using flow-cytometry. There was a significant increase in the number of cells in G1/G0 phase, along with 
a decrease in the number of cells in the S phase. Notably, OSMI1 equally impacted cell cycle phase distribution in 
both the MDA-MB-231 and the MCF7 cell lines (Fig. 3E,F).
In conclusion, we identified changes in the cell cycle as a major response to OGT inhibition. However, treat-
ment with OSMI1 caused cell cycle arrest in both hormone receptor-negative and -positive cells. This response 
can therefore not explain the higher sensitivity of TNBC cells to OGT inhibition, indicating that other factors 
contribute to the differential response.
Figure 3. OGT inhibition differentially affects proteome and phospho-proteome in MCF7 and MDA-MB-231. 
(A) Proteins whose expression changed by 28% or more compared to the control samples in MDA-MB-231 
following 24 hours of treatment with 20 µM OSMI1, were selected. Corresponding proteins in MCF7 are shown 
in the same figure. RPPA array, n = 3, error bars - SEM. *p < 0.05; **p < 0.01, unpaired t-test. Significance 
indicates comparison of the relative protein expression changes in MDA-MB-231 and MCF7. (B) Total 
O-GlcNAcylation and phospho-PS6 (S235-S326) in MDA-MB-231 and MCF7 following treatment with 20 µM 
OSMI1 for 24 hours. (C) Phospho-PS6 (S235-S236) in MDA-MB-231 after treatment with 20 µM OSMI1 
for 9, 16, 24, 32, 40 and 48 hours. (D) Viability in MCF7 and MDA-MB-231 following 72 hours of treatment 
with Everolimus (Ev), OSMI1 and the combination. MTS assay, error bars - SEM, n = 3. *p < 0.05, unpaired 
t-test. (E,F) Cell cycle distribution in MCF7 (E) and MDA-MB-231 (F), after 24 hours of treatment with 20 µM 
OSMI1. n = 3, error bars - SEM. *p < 0.05; **p < 0.005, unpaired t-test.
7Scientific RepoRts |          (2019) 9:5670  | https://doi.org/10.1038/s41598-019-42153-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
Regulation of HES1 in triple-negative breast cancer cells. Searching for potential mediators of high 
sensitivity of the TNBC cells to OGT inhibition, we identified transcriptional repressor HES1, as a protein that 
was strongly decreased in TNBC, but not in the receptor-positive cells (Fig. 3A). In the RPPA data, HES1 was 
down-regulated by 30% in MDA-MB-231 following both the treatment with OSMI1 and the OGT knock-down. 
In MCF7, however, HES1 was mildly increased after treatment with OSMI1 and slightly down-regulated after the 
OGT knock-down (Fig. 3A, Supplementary Fig. S2A). We confirmed that both OSMI1 and OGT knock-down 
caused a greater than 50% decrease in HES1 protein expression in the TNBC cells, while HES1 expression in the 
receptor-positive cells remained unchanged, or modestly elevated (Fig. 4A,B). In addition, HES1 was promi-
nently down-regulated in all tested TNBC cell lines following 24 hours of treatment with OSMI1 (Supplementary 
Fig. S3B). To confirm the link between HES1 and OGT, we evaluated gene expression of the phosphatase and ten-
sin homolog (PTEN). PTEN expression is known to be negatively regulated by HES136. In accordance with this, 
both the OGT knockdown and treatment with OSMI1 increased PTEN expression (Supplementary Fig. S3A). To 
our knowledge, this is the first instance where OGT has been shown to regulate PTEN.
In order to determine how inhibition of OGT causes down-regulation of HES1 in TNBC cells, we tested 
whether HES1 is modified with O-GlcNAc, using immuno-precipitation and confocal microscopy, but did not 
observe evidence of this (data not shown). Next, we assessed if inhibition of OGT affects transcriptional regu-
lation of HES1, however, it did not affect HES1 mRNA levels (Supplementary Fig. S3A). HES1 is an unstable 
protein, with a half-life of ~2 hours, undergoing continuous proteasomal degradation at the end of this period37. 
It has been reported that OGT inhibits proteasomal activity38, which prompted us to suggest that OSMI1 induces 
proteasomal degradation of HES1. Indeed, inhibition of the proteasome activity with MG-132 completely pre-
vented down-regulation of HES1 in response to OSMI1 (Fig. 4C). This confirmed that OGT regulates HES1 
protein stability through proteasomal degradation, enabling constitutive expression of this transcription factor.
Earlier we found that the combined cytotoxicity of OSMI1 and PR inhibitor was associated with a promi-
nent increase in DNA damage (Fig. 2E,F). Inhibition of OGT enhanced the severity of DNA damage induced 
by MF in MCF7 cells. HES1 interacts with the fanconi anemia core complex, which facilitates the repair of DNA 
crosslinks39. We therefore hypothesized that inhibition of HES1 activity could promote DNA damage. HES1 
expression is regulated by Notch signaling. Ligand-activated cleavage of Notch receptors by γ-secretase, and the 
following activation of down-stream signaling, can be blocked by γ-secretase inhibitor (GSI)40. Treatment with 
GSI alone or a knock-down of HES1 induced mild DNA damage, however, it was greatly potentiated by the 
simultaneous knock-down of OGT or treatment with OSMI1, respectively. In both cases the combined treatment 
resulted in a complete loss of HES1 (Supplementary Fig. S3E).
Next, we moved on to assess whether targeting HES1 can replicate the cytotoxic effects observed after OGT 
inhibition. In the MDA-MB-231 cells, knock-down of HES1 potently induced apoptosis (Fig. 5B). To confirm 
that this response is not only specific to MDA-MB-231, we performed HES1 knock-downs in two additional 
TNBC cells lines, BT549 and MDA-MB-468, as well as in the MCF7 cells. Based on visual inspection, we observed 
fewer cells in response to the HES1 knock-down and possible induction of cell death (Fig. 5A). Indeed, the 
knock-down of HES1 induced PARP cleavage in all of the breast cancer cell lines tested (Fig. 5C). In addition, 
Figure 4. HES1 is selectively regulated by OGT in TNBC cells. (A) Relative protein HES1 expression following 
24 hours of treatment with 20 µM OSMI1 (upper panel, error bars: SEM, n = 4; **p < 0.005, unpaired t-test) or 
72 hours after a transient OGT knock-down (lower panel, error bars: St. dev, n = 2). (B) HES1 in MDA-MB-231 
and MCF7 after 24 hours of treatment with 20 µM OSMI1. (C) HES1 protein expression in MDA-MB-231 
following 2 hours of treatment with OSMI1, proteasome inhibitor MG-132, DMSO or combinations. Error bars 
- SEM, n = 3; *p < 0.05, unpaired t-test.
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HES1 knockdown sensitized MCF7 cells to OSMI1 (Supplementary Fig. S3C,D). Taken together, these results 
suggest that HES1 is important for proliferation of both TNBC and receptor-positive cell lines.
In breast cancer, HES1 has been implicated in epithelial-to-mesenchymal transition41, stimulation of inva-
sion42 and resistance to HER2 inhibitors43. In addition, HES1 has been shown to be important for prolifera-
tion of the TNBC cells42, which encouraged us to test if HES1 can be used as a prognostic marker. In patients 
with receptor-positive breast cancer, high level of HES1 expression correlates with longer relapse-free survival 
Figure 5. Loss of HES1 affects BC cell viability. (A) BC cells pictured after 72 hours of transient HES1 knock-
down. (B) Apoptosis in MDA-MB-231 cells after 4 days of transient HES1 knock-down. Error bars - SEM, n = 3; 
**p < 0,005, unpaired t-test. (C) Total length and cleaved PARP and HES1 following 3 days of transient HES1 
knock-down in MCF7, MDA-MB-468 and BT-549 cell lines. Representative of two biological replicates. (D, E) 
Relapse-free survival (RFS) in ER-positive, PR-positive (D), and ER-negative and PR-negative (E) breast cancer. 
Both cohorts excluded the HER-2-amplified BCs and patients that did not receive systemic treatment. Plots 
built using the online KM-plotter tool24.
9Scientific RepoRts |          (2019) 9:5670  | https://doi.org/10.1038/s41598-019-42153-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
(Fig. 5D). In the receptor-negative breast cancers, however, high expression of HES1 was strongly associated with 
poor prognosis (Fig. 5E). Based on these data, we propose that HES1 has a distinct function in TNBC and in 
the hormone receptor-positive cells.
Discussion
Abnormally high levels of O-GlcNAcylation in breast cancer have been linked to sustained proliferation18, inva-
sion and metastasis13. However, these studies do not account for the characteristic diversity and heterogeneity of 
breast cancers. Here we found that OGT inhibition or knock-down is significantly more toxic to TNBC cells than 
to the hormone receptor-positive cells (Fig. 1C). While it is possible to sensitize receptor-positive cells to OGT 
inhibition by co-targeting either ER or PR, the combined effect of hormone receptor and OGT inhibition falls 
short of the prominent cyto-toxicity observed in the TNBC cells. This suggests that there are multiple contribut-
ing factors that dictate sensitivity of breast cancer cells to the decrease of protein O-GlcNAcylation.
Aiming to broaden our understanding of the response to OGT inhibition or knock-down, we performed a 
protein RPPA assay. Confirming previous reports that link OGT to the regulation of cell cycle (reviewed in44), we 
show that cell cycle phase distribution is affected upon OGT inhibition, leading to arrest in G1 phase (Fig. 3E,F). 
Notably, these changes were universal for the receptor-positive and -negative cell lines. In addition, we demon-
strate that inhibition of OGT blocks the mTORC1 signaling. mTORC1 is a key regulator of protein synthesis, 
supporting up-regulated rate of translation in cancer tissues45. Earlier studies have detailed the cross-talk between 
OGT and mTORC1 in cancer cells, showing that de-regulation of either pathway has a similar effect on the other 
one46–48. Here we observed that OGT inhibition leads to a decrease in mTORC1 signaling in the TNBC cells, but 
not in the hormone receptor-positive MCF7 cells. This was apparent from a decrease in phosphorylation of PS6, 
indicating that p-PS6 level can serve as a biomarker of response to OGT inhibition in breast cancer cells.
OGT has been shown to limit the DNA damage response and facilitate DNA repair by directly inducing 
O-GlcNAcylation of H2AX and preventing its phosphorylation at the same site14,15. On its own, inhibition of 
OGT has led to modest DNA damage in all of the tested cell lines. This was greatly increased by additional treat-
ment with MF in MCF7, and accompanied with prominent apoptosis (Fig. 2D–F). Here we found that OGT inhi-
bition or knock-down leads to the proteasomal degradation of HES1 in the TNBC cells. Notch1-HES1 signaling is 
known to prevent DNA damage, while Notch1 inhibition or knock-down leads to accumulation of double-strand 
breaks after irradiation49. This response was shown to rely on HES1 interaction with the fanconi-anemia com-
plex, which facilitates DNA repair39. In concert with these studies, simultaneous loss of OGT and HES1 resulted 
in extensive DNA damage in TNBC cells (Supplementary Fig. S3E). Our findings raise a possibility of targeting 
OGT to increase DNA damage in the TNBC cells.
In conclusion, we have established that OGT inhibition has a differential effect on breast cancer cells of differ-
ent phenotypes, with TNBC cells having a particularly high sensitivity. We identify the transcriptional repressor 
HES1 and DNA damage as mediators of the response to OGT inhibition in these cells. The sheer complexity of 
OGT-mediated signaling makes it a challenging enzyme to study. More comprehensive breast cancer models are 
required to unravel the response to inhibition of OGT, and determine its usefulness for the treatment of TNBC.
Data Availability
The patient survival datasets analyzed during the current study are available in the KM-plotter repository (http://
kmplot.com/analysis/). The full RPPA results and the confocal microscopy images, showing the lack of O-GlcNAc 
modification on HES1, are available from the corresponding author on reasonable request. All other data generat-
ed or analyzed during this study are included in this published article and its Supplementary Files.
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